Eleven newborns admitted consecutively to the neonatal unit with respiratory failure and severe persistent pulmonary hypertension (PPHN) were included in a clinical trial to assess the efficacy of magnesium sulphate (MgSO4) in the treatment of PPHN. A loading dose of 200 mg/kg MgSO4 was given over 20 minutes, followed by a continuous infusion of 20-150 mg/kg/hour to obtain a magnesium blood concentration between 3 5 and 5 5 mmol/l. Mean (SD) duration of treatment was 75-5 (19.8) hours. No other vasodilatory drug was administered before or during the treatment and patients were not hyperventilated. Mean (SEM) PaO2 values significantly increased from 42-6 (8.8) before treatment to 70*3 (24.1) mm Hg after 24 hours, with no change in pH or Pco2. Oxygen index and alveolar-arterial oxygen gradient (A-aDo2) were significantly lower after 24 hours; respectively, 46-8 (15.2) to 28-0 (9.0) and 624-3 (11-3) to 590 (58) nmn Hg. Mean airway pressure could be significantly reduced from 19*5 (3-1) to 13-9
(3.9) cm H20 after 72 hours. Mean ventilatory time support was 131 hours and mean total oxygen dependency 10 days. No systemic hypotension nor any other adverse effect were noted. All infants survived and the neurodevelopmental assessment was normal at 6 and 12 months of age.
It is concluded that magnesium sulphate is a non-aggressive and low-cost treatment of short duration which is easy to apply. It may have a role in the various treatment of PPHN.
Persistent pulmonary hypertension of the newborn is a potentially fatal complication of the circulatory adaptation. It leads to a profound hypoxaemia secondary to the right to left shunting across the foramen ovale and/or the ductus arteriosus as a result of the abnormally raised pressures in the pulmonary vascular bed. Infants with an A-aDo2 above 600 mm Hg for more than 12 hours and oxygen index above 40 have been reported to have a mortality greater than 80%.1 2 Different therapeutic approaches, including various vasodilatory agents34 and extra-corporeal membrane oxygen (ECMO)5 6 have been advocated, with variable success. More recently inhaled nitric oxide (NO) treatment has been given to term and preterm neonates with encouraging results7-9 and its use and potentially toxic effects studied.'0 At high serum concentrations, magnesium is a muscle relaxant, a sedative, and a potent vasodilatory agent. "l It has been used for a long time in hypertension induced by pregnancy'2 with variable success but no adverse effect on the fetus and the newborn.13 Animal studies have shown that magnesium can prevent and reduce hypoxia induced pulmonary hypertension'4-6 and two clinical reports have shown its benefit in the rescue treatment of PPHN in neonates.17 18 Recently we described in a preliminary report its possible use as a first line treatment without alkalinisation or administration of other vasodilatory drugs. ' were 8 1 at one minute and 8&2 at five minutes.
Only one term infant had perinatal asphyxia (Apgar 8/3/5). Seven infants presented with aspiration syndrome, two with hyaline membrane disease, one with pneumonia and one with Streptococcus B sepsis. Informed consent was obtained from all parents. All patients were first given routine supportive treatment including: (1) haemodynamic support by volume expansion up to 20 to 30 ml/kg and, if necessary, with continuous dobutamine infusion at 5 to 20 mg/kg/minute; (2) sedation with morphine infusion at 10 to 20 mg/kg/hour with additional doses of Od mg/kg if necessary and; (3) appropriate ventilatory support (Bear Cub infant ventilator). Before and during MgSO4 treatment, heart rate, mean arterial blood pressure (MABP), temperature, and ventilator settings with inspired oxygen fraction (FIO2), respiratory rate, peak inspiratory pressure (PIP), positive end expiratory pressure (PEEP), and mean airway pressure (Paw) were recorded at two hour intervals during the first day of treatment and then four to six times a day. The blood gas measurements (pH, PaO2, Pco2) were obtained through an indwelling arterial umbilical catheter (Argyle 3-5 or 5-5 French guage) positioned at L3 to L4, and measured with an ABL 300 acid base laboratory analyser.
All the variables and results are expressed as mean±one standard deviation (SD). Before MgSO4 infusion was begun, all infants were ventilated with 100% FiO2 at a rate of 45 1 (15*7)/minute with high PIP of 35-9 (4A4) cm H20 and a PEEP of 3-5 (0 9) cm H20. Mean H20. Blood gas analysis showed a pH value of 7-34 (0 09) and a Pco2 of 45-1 (12-0) mm Hg. All infants survived, had a normal neurological examination, and normal head ultrasound scans at hospital discharge.
Ten of the 11 infants were examined in the developmental unit between 6 and 12 months of age and all had a normal development. One child lives abroad and is normal according to his parents and paediatrician.
Discussion
The regulation of the pulmonary circulation before and after birth reflects a balance between factors producing active pulmonary vasoconstriction and vasodilation.22 Despite a better understanding of the underlying pathophysiology and the various treatments that have been proposed,23 pulmonary hypertension remains a potentially fatal complication among newborns. 24 In the absence of specific pulmonary vasodilators, ECMO and other vasodilating agents given by inhalation have been used or are currently under investigation. 25 26 At high serum concentrations, magnesium is a muscle relaxant, a sedative, and a potent vasodilatory drug. Its effects on the vascular system have been studied in animals.15 16 It is a modulator of vascular contraction and an activator of many cellular processes, including cation transport and modulation of membrane excitability, and it is a physiological calcium antagonist. 1 ' MgSO4 has already been given as rescue treatment to newborns with severe PPHN. 18 In this study we used magnesium without any other vasodilatory agent or hyperalkalinisation. Our 11 patients all presented with a severe PPHN, evidenced by refractory hypoxaemia with a high oxygen index and A-aDo2. After a loading dose of MgSO4, the magnesium blood concentration of 3-5-5 5 mmol/l was rapidly obtained and easily maintained with a continuous infusion. During treatment, a rapid increase in PaO2 was observed, allowing a progressive reduction in Paw and Fio2, resulting in a decrease of severity indices. Furthermore, with these high magnesium blood concentrations, babies were more stable and had fewer PaO2 fluctuations. This was probably due to the sedative and relaxing effects of magnesium. Nursing in the prone position was then possible, shortening the duration of ventilation and oxygen dependency that are usually required by these very sick neonates.
None of the known side effects of high dose magnesium was observed. The slight decrease in heart rate was easily corrected by dobutamine support. Blood pressure remained stable and increased progressively with postnatal age. Feeding was well tolerated.
Despite high indices of mortality, all infants survived. At discharge from hospital they all had normal neurological findings and normal brain ultrasonography. None of them developed chronic lung disease and at follow up all had normal development. Sensory hearing loss has been reported in infants with PPHN.27 This has not yet been detected in our patients.
In conclusion, this report provides evidence that magnesium can play part in the treatment of persistent pulmonary hypertension of the newborn. It is a non-aggressive treatment of short-duration and low cost. Based on these encouraging results, all patients presenting to our unit with PPHN are currently receiving MgSO4 as the first drug of choice in a prospective protocol. Clinical controlled studies in life threatening conditions, however, are difficult to perform. Nevertheless, comparison between different approaches in the treatment of PPHN is certainly necessary for the evaluation of their respective benefits.
Experimental studies of magnesium and its possible interactions with natural vasodilators, such as prostacyclins, nitric oxide, and the guanylate cyclase pathway, would be suitable areas to investigate in the future.
